Caris Life Sciences (CAI) Non-Current Debt (2024 - 2026)

Caris Life Sciences' Non-Current Debt history runs 3 years deep, the most recent figure standing at $381.1 million for Q1 2026.

• On a quarterly basis, Non-Current Debt changed N/A year-over-year to $381.1 million in Q1 2026; TTM through Mar 2026 was $381.1 million, a N/A change from a year earlier, with the FY2025 full-year figure at $378.8 million, up 1.52% from the prior year.
• Non-Current Debt improved to $381.1 million in Q1 2026 per CAI's latest filing, from $378.8 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $381.1 million in Q1 2026 and bottomed at $373.1 million in Q4 2024.
• The 3-year median for Non-Current Debt is $375.9 million (2025), against an average of $376.5 million.
• Biggest YoY gain for Non-Current Debt was 1.52% in 2025; the steepest drop was 1.52% in 2025.
• Year by year, Non-Current Debt stood at $373.1 million in 2024, then grew by 1.52% to $378.8 million in 2025, then advanced by 0.59% to $381.1 million in 2026.
• Per Business Quant, the three latest CAI Non-Current Debt figures stand at $381.1 million (Q1 2026), $378.8 million (Q4 2025), and $375.9 million (Q3 2025).